Buy KPV peptide.

Buy KPV peptide: vial, pen or nasal spray

The vial and nasal spray each contain 10 mg KPV. The prefilled pen contains 15 mg in 3 mL, at 5 mg/mL. The vial arrives as powder; the other two formats are already mixed. All three are research-labelled products. [1]

Research-labelled products. Drawings show the formats; they are not product photographs.

Three formats, one ingredient

The pen holds 50% more KPV than either 10 mg format. That is a difference in total content. It does not establish greater absorption, stronger effects or a longer treatment course. The different routes do not have a validated milligram-for-milligram conversion.

KPV 10 mg vial: powder with adjustable concentration

The sealed vial contains white freeze-dried KPV powder. The label specifies 10 mg of the three-amino-acid sequence Lys-Pro-Val. No BPC-157, TB-500 or GHK-Cu is listed. The supplied certificate identifies this material as H-KPV-OH. [1] [2]

The final liquid volume controls the concentration. A 10 mg vial prepared to 2 mL calculates to 5 mg/mL. At 1 mL it would be 10 mg/mL; at 3 mL it would be about 3.33 mg/mL. Adding water changes the volume representing an amount of KPV. It does not increase the 10 mg total.

For a 500 mcg calculation, the 2 mL example gives 0.1 mL. A 10 mg vial contains twenty such mathematical portions before transfer losses and discard limits. That calculation describes quantity; it does not select a daily dose or a cycle.

10 mg vial preparation → · Enter your target amount in the KPV calculator →

KPV 15 mg pen: 3 mL at 5 mg/mL

The pen is already mixed in water with 0.9% benzyl alcohol. No water needs adding to the cartridge. The stated 5 mg/mL means each millilitre contains 5 mg KPV; multiplying by the 3 mL fill gives 15 mg in total. [1]

The supplied device configuration has 300 marked units across 3 mL: 0.01 mL, or 50 mcg KPV, per marked unit. On that scale, ten marked units represent 0.1 mL and 500 mcg. A mechanical click has not been verified as one marked unit; use the marked scale specified for this device.

At a 500 mcg target amount, 15 mg represents thirty mathematical portions. Actual output can be lower because of priming and liquid left inside the cartridge. A larger pen is not automatically better value if its applicable discard date leaves part of the liquid unused.

A vial prepared to 2 mL happens to match this pen's 5 mg/mL concentration. A vial prepared to 1 mL would be twice as concentrated: 0.1 mL would contain 1 mg. Copying a volume between formats therefore works only when both concentrations match. The KPV dosage and measurement guide separates milligrams, micrograms, millilitres and U-100 markings.

KPV 10 mg nasal spray: bottle total and pump amount

The spray contains 10 mg KPV per bottle in a prepared water-based solution with 0.9% benzyl alcohol. The exact bottle fill, pump volume and micrograms per press have not been supplied. Ten milligrams is the bottle total, not the amount released by one press. [1]

The safety sheet lists KPV at no more than 0.1% weight/volume. That is a classification limit based on a nominal minimum fill, not a precise pump specification. It cannot be used to assign a 100 mcg, 150 mcg or 500 mcg spray amount.

The spray removes the powder-mixing step. It does not establish that a nasal amount equals the same injected amount, or that the nose delivers KPV to the gut. A finished-spray assay and pump-output specification would make the format comparison more complete.

Compare cost per milligram and usable quantity

Divide the vial or spray price by 10; divide the pen price by 15. This gives cost per labelled milligram of KPV. Two pens and three vials each contain 30 mg in total.

Include mixing materials, delivery and wasted product in a real cost comparison. The spray's price per milligram compares bottle contents; it cannot establish cost per absorbed dose. Current selling prices and ordering destinations are not provided here.

A 10 mg label does not mean a ten-day supply. Supply depends on the amount removed, how often it is removed and the product's usable life. At 250 mcg per calculation, the vial contains forty mathematical portions; at 500 mcg, twenty. The pen gives sixty and thirty respectively. These are inventory calculations, not dosing schedules. More water makes each portion larger in volume without changing those counts.

KPV alone and KLOW contain different amounts

KPV is one peptide. KLOW is a four-peptide blend containing KPV, GHK-Cu, BPC-157 and TB-500. The KLOW 80 mg vial contains 10 mg KPV alongside 70 mg of the other ingredients. It does not contain 80 mg KPV.

One milligram of that KLOW blend contains 125 mcg KPV. One milligram of this standalone KPV contains 1,000 mcg KPV by label amount. That eightfold difference matters when comparing products or entering an amount into a calculator. Standalone KPV also allows its amount to change without increasing three other peptides.

Store powder frozen and prepared formats refrigerated

Prepared KPV liquid is described as clear, colourless to faintly yellow. Cloudiness or a change from that appearance needs resolution; the pen instructions require disposal after freezing. No verified 28-day or 30-day in-use limit is supplied. The powder's retest date cannot be transferred to a mixed vial, pen or spray. [1]

Redacted KPV certificate of analysis

REDACTED COPY · IN-HOUSE REPORT

KPV — powder lot PL-2609-059

99.79% RP-HPLC area purity

Label claim10 mg per powder vialLC-MS identity342.6 DaEndotoxin0.05 EU/mgSterility testNo growth after 14 daysAnalysis date16 September 2026Sampled units2 of 250

Two sampled powder vials from lot PL-2609-059. Finished-pen and finished-spray content, sterility, stability and batch linkage are not established by this report.

Open redacted COA

Certificate PL-26-00059 covers powder lot PL-2609-059, with two vials sampled from a 250-unit lot. It records 99.79% RP-HPLC area purity, a 342.6 Da identity result, 0.05 EU/mg endotoxin, 1.7% water and no growth after 14 days in the sterility test. [2]

The report is an in-house analysis, with no independent laboratory attachment. Its purity figure describes the KPV peak's share of the detected chromatogram area. A separate quantitative assay confirming 10 mg in each vial is not listed.

Purity, amount and microbiology are separate results. A 99.79% peak-area result does not mean the vial contains 9.979 mg KPV, and it does not substitute for the listed sterility test. The endotoxin result is 0.05 EU/mg; it is not the same measurement as bacterial growth. Keep each result attached to its method and the tested powder lot.

The redacted two-page PDF is shared beside all three formats as a powder-lot reference. It does not test a finished pen or nasal spray, confirm their batch linkage, measure spray output or establish stability after opening. The document retains its original dates, methods and signatures.